A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease
BackgroundImmune checkpoints are a set of costimulatory and inhibitory molecules that maintain self-tolerance and regulate immune homeostasis. The expression of immune checkpoints on T cells in malignancy, chronic inflammation, and neurodegenerative diseases has gained increasing attention.ResultsTo characterize immune checkpoints in neurodegenerative diseases, we aimed to examine the expression of the immune checkpoint PD-1/PD-L1 in peripheral T cells in different Alzheimer’s disease (AD) patients. To achieve this aim, sixteen AD patients and sixteen age-matched healthy volunteers were enrolled to analyze their CD3+ T cells, CD3+CD56+ (neural cell adhesion molecule, NCAM) T cells, CD4+/CD8+ T cells, and CD4+/CD8+CD25+ (interleukin-2 receptor alpha, IL-2RA) T cells in this study. The expression of PD-1 on T cells was similar between the AD patients and healthy volunteers, but increased expression of PD-L1 on CD3+CD56+ T cells (natural killer T cells, NKT-like), CD4+ T cells (helper T cells, Th), CD4+CD25+ T cells, and CD8+ T cells (cytotoxic T lymphocytes, CTL) was detected in the AD patients. In addition, we found negative correlations between the AD patients’ cognitive performance and both CD8+ T cells and CD8+CD25+ T cells. To identify CD8+ T-cell phenotypic and functional characteristic differences between the healthy volunteers and AD patients in different stages, a machine learning algorithm, t-distributed stochastic neighbor embedding (t-SNE), was implemented. Using t-SNE enabled the above high-dimensional data to be visualized and better analyzed. The t-SNE analysis demonstrated that the cellular sizes and densities of PD-1/PD-L1 on CD8+ T cells differed among the healthy, mild AD, and moderate AD subjects.ConclusionsOur results suggest that changes in PD-1/PD-L1-expressing T cells in AD patients’ peripheral blood could be a potential biomarker for monitoring disease and shed light on the AD disease mechanism. Moreover, these findings indicate that PD-1/PD-L1 blockade treatment could be a novel choice to slow AD disease deterioration.
82
- Oct 1, 2001
- Journal of the Formosan Medical Association
582
- 10.1073/pnas.0931259100
- Apr 15, 2003
- Proceedings of the National Academy of Sciences
123
- 10.1182/blood.v86.9.3493.bloodjournal8693493
- Nov 1, 1995
- Blood
244
- 10.1016/j.jneuroim.2007.05.011
- Jun 19, 2007
- Journal of Neuroimmunology
1689
- 10.1016/s0140-6736(14)60958-2
- Jul 15, 2014
- The Lancet
478
- 10.1111/imm.12233
- Apr 24, 2014
- Immunology
27
- 10.1038/s41598-021-81961-7
- Jan 27, 2021
- Scientific Reports
149
- 10.1038/jid.2009.30
- Jul 1, 2009
- Journal of Investigative Dermatology
104
- 10.1016/0092-8674(83)90478-6
- Feb 1, 1983
- Cell
20
- 10.1159/000127742
- Jan 1, 1974
- European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
- Research Article
1
- 10.1016/j.jcyt.2024.07.010
- Jul 24, 2024
- Cytotherapy
PD-1/PD-L1 interaction score and NKT-like cell infiltration predict immunotherapy efficacy in non-small cell lung cancer patients
- Research Article
- 10.1007/s12035-025-05153-4
- Jun 19, 2025
- Molecular neurobiology
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease, and previous research has shown that T cell-mediated immunity plays a key role in PD pathology. Programmed cell death protein 1 (PD-1) is a type I transmembrane protein that inhibits T lymphocyte inflammatory activity, and PD-1 deletion can reduce dopamine levels in mouse brains. However, the clinical status of PD-1 in PD patients remains obscure. To understand the clinical role of PD-1, flow cytometry (FCM) was used to assess peripheral blood mononuclear cells (PBMCs) from 16 patients with Parkinson's disease and 16 controls in our study. With respect to PD-1 expression on peripheral T lymphocytes, we found a statistically greater proportion of PD-1 on CD8+ T, CD4+ T, and T helper (Th) 1 cells in the PD group compared to the control group (p < 0.05), and the proportion of CD4+ PD-1+ T cells was positively correlated with Parkinson's Disease Sleep Scale (PDSS) scores (r = 0.5277, p = 0.0454). Moreover, the PD patients had a lower percentage of CD3+ T cells (p = 0.0007) among PBMCs. Furthermore, the expression level of PD-1 was positively correlated with the expression of interferon-gamma (IFN-γ) in CD4+ T cell subsets from patients with PD (r = 0.6765, p = 0.0051) and total subjects (r = 0.4674, p = 0.0070), while there was no relationship between PD-1 and regulatory T (Treg) cells in the PD group. In conclusion, our results indicated that the PD-1 expression on peripheral T lymphocytes may be involved in the pathogenesis of PD.
- Research Article
30
- 10.1038/s41467-023-36759-8
- Mar 9, 2023
- Nature Communications
Systemic immunity supports lifelong brain function. Obesity posits a chronic burden on systemic immunity. Independently, obesity was shown as a risk factor for Alzheimer’s disease (AD). Here we show that high-fat obesogenic diet accelerated recognition-memory impairment in an AD mouse model (5xFAD). In obese 5xFAD mice, hippocampal cells displayed only minor diet-related transcriptional changes, whereas the splenic immune landscape exhibited aging-like CD4+ T-cell deregulation. Following plasma metabolite profiling, we identified free N-acetylneuraminic acid (NANA), the predominant sialic acid, as the metabolite linking recognition-memory impairment to increased splenic immune-suppressive cells in mice. Single-nucleus RNA-sequencing revealed mouse visceral adipose macrophages as a potential source of NANA. In vitro, NANA reduced CD4+ T-cell proliferation, tested in both mouse and human. In vivo, NANA administration to standard diet-fed mice recapitulated high-fat diet effects on CD4+ T cells and accelerated recognition-memory impairment in 5xFAD mice. We suggest that obesity accelerates disease manifestation in a mouse model of AD via systemic immune exhaustion.
- Supplementary Content
11
- 10.3390/ijms241310905
- Jun 30, 2023
- International Journal of Molecular Sciences
Our research over the past decade has compellingly demonstrated the potential of Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor agonists in Alzheimer’s disease (AD) treatment. These agonists facilitate the conversation of pro-inflammatory monocytes into patrolling monocytes, leading to the efficient clearance of amyloid-β (Aβ) in the AD-affected cerebrovascular system. This approach surpasses the efficacy of targeting Aβ formation, marking a significant shift in therapeutic strategies. Simultaneously, inhibitors of PD-1/PD-L1 immune check point or glycogen synthase kinase 3 beta (GSK3β), which modulates PD-1, have emerged as potent AD treatment modalities. PD-1 inhibitor exhibits a profound potential in monocytes’ recruitment to the AD-afflicted brain. Recent evidence suggests that an integrated approach, combining the modulation of NOD2 and PD-1, could yield superior outcomes. This innovative combinatorial therapeutic approach leverages the potential of MDP to act as a catalyst for the conversion of inflammatory monocytes into patrolling monocytes, with the subsequent recruitment of these patrolling monocytes into the brain being stimulated by the PD-1 inhibitor. These therapeutic interventions are currently under preclinical investigation by pharmaceutical entities, underscoring the promise they hold. This research advocates for the modulation, rather than suppression, of the innate immune system as a promising pharmacological strategy in AD.
- Research Article
28
- 10.1186/s12979-024-00445-0
- Jun 14, 2024
- Immunity & Ageing
Alzheimer’s disease (AD) is a serious brain disorder characterized by the presence of beta-amyloid plaques, tau pathology, inflammation, neurodegeneration, and cerebrovascular dysfunction. The presence of chronic neuroinflammation, breaches in the blood-brain barrier (BBB), and increased levels of inflammatory mediators are central to the pathogenesis of AD. These factors promote the penetration of immune cells into the brain, potentially exacerbating clinical symptoms and neuronal death in AD patients. While microglia, the resident immune cells of the central nervous system (CNS), play a crucial role in AD, recent evidence suggests the infiltration of cerebral vessels and parenchyma by peripheral immune cells, including neutrophils, T lymphocytes, B lymphocytes, NK cells, and monocytes in AD. These cells participate in the regulation of immunity and inflammation, which is expected to play a huge role in future immunotherapy. Given the crucial role of peripheral immune cells in AD, this article seeks to offer a comprehensive overview of their contributions to neuroinflammation in the disease. Understanding the role of these cells in the neuroinflammatory response is vital for developing new diagnostic markers and therapeutic targets to enhance the diagnosis and treatment of AD patients.
- Research Article
6
- 10.1038/s41593-024-01847-5
- Jan 6, 2025
- Nature neuroscience
The central nervous system (CNS) is endowed with its own resident innate immune cells, the microglia. They constitute approximately 10% of the total cells within the CNS parenchyma and act as 'sentinels', sensing and mitigating any deviation from homeostasis. Nevertheless, under severe acute or chronic neurological injury or disease, microglia are unable to contain the damage, and the reparative activity of monocyte-derived macrophages (MDMs) is required. The failure of the microglia under such conditions could be an outcome of their prolonged exposure to hostile stimuli, leading to their exhaustion or senescence. Here, we describe the conditions under which the microglia fall short, focusing mainly on the context of Alzheimer's disease, and shed light on the functions performed by MDMs. We discuss whether and how MDMs engage in cross-talk with the microglia, why their recruitment is often inadequate, and potential ways to augment their homing to the brain in a well-controlled manner.
- Research Article
37
- 10.3390/ijms24032743
- Feb 1, 2023
- International Journal of Molecular Sciences
CD56+ T cells are generally recognized as a distinct population of T cells and are categorized as NKT-like cells. Although our understanding of NKT-like cells is far from satisfactory, it has been shown that aging and a number of disease situations have impacted these cells. To construct an overview of what is currently known, we reviewed the literature on human NKT-like cells. NKT-like cells are highly differentiated T cells with "CD1d-independent" antigen recognition and MHC-unrestricted cell killing. The genesis of NKT-like cells is unclear; however, it is proposed that the acquisition of innate characteristics by T cells could represent a remodeling process leading to successful aging. Additionally, it has been shown that NKT-like cells may play a significant role in several pathological conditions, making it necessary to comprehend whether these cells might function as prognostic markers. The quantification and characterization of these cells might serve as a cutting-edge indicator of individual immune health. Additionally, exploring the mechanisms that can control their killing activity in different contexts may therefore result in innovative therapeutic alternatives in a wide range of disease settings.
- Research Article
13
- 10.1016/j.ymthe.2024.09.026
- Sep 28, 2024
- Molecular Therapy
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders
- Research Article
6
- 10.1007/s40005-023-00631-0
- Sep 1, 2023
- Journal of Pharmaceutical Investigation
Recent advances in Alzheimer’s disease pathogenesis and therapeutics from an immune perspective
- Research Article
- 10.1002/brb3.70042
- Sep 30, 2024
- Brain and behavior
Persistent pain is a prominent symptom of knee osteoarthritis (KOA) and has been associated with cognitive decline in individuals with KOA. The amygdala, a complex structure consisting of nine subnuclei, and programmed cell death protein-1 (PD-1) levels play crucial roles in pain regulation and cognitive processing. This study aims to investigate the relationships among amygdala subregion volumes, cognitive function, and PD-1 levels to elucidate the underlying mechanism of cognitive decline in KOA. In this cross-sectional study, we recruited 36 patients with KOA and 25 age/gender-matched healthy controls for neuropsychological tests, structural magnetic resonance imaging scanning, and measurement of serum PD-1 levels. We used the atlas provided by FreeSurfer software to automatically segment the amygdala subnuclei. Subsequently, we compared the volumes of amygdala subregions between groups and explored their correlation with clinical scores and PD-1 levels. Compared to healthy controls, individuals with KOA exhibited significantly lower scores on global cognition tasks, such as long-delay free recall, short-delay free recall, and immediate recall tasks. Moreover, they displayed decreased volumes in lateral nucleus basal nucleus paralaminar nucleus while showing increased volumes in accessory basal nucleus, central nucleus, medial nucleus, and cortical nucleus. Within the KOA group specifically, paralaminar volume was negatively correlated with immediate recall scores; pain scores were negatively correlated with global cognition; basal volume was negatively correlated with PD-1 levels. Our findings highlight those alterations in amygdala subregion volumes along with changes in serum PD-1 levels may contribute to observe cognitive decline among individuals suffering from KOA.
- Research Article
22
- 10.1111/j.1440-1819.2011.02253.x
- Aug 1, 2011
- Psychiatry and Clinical Neurosciences
Editorial: New drugs for Alzheimer's disease in Japan
- Research Article
144
- 10.1016/j.neuron.2014.01.026
- Mar 1, 2014
- Neuron
Intrinsic Connectivity Identifies the Hippocampus as a Main Crossroad between Alzheimer’s and Semantic Dementia-Targeted Networks
- Research Article
50
- 10.1001/archneur.60.11.1585
- Nov 1, 2003
- Archives of Neurology
Calculation deficits are a common early manifestation of Alzheimer disease (AD). To investigate oral and written calculation skills in AD patients using quantitative and qualitative methods. Comparison among controls, patients with mild AD, and patients with moderate AD on measures of arithmetic skill. Tertiary care university medical center. Twenty patients with AD (11 with mild AD, 9 with moderate AD) and 23 elderly controls. Tests of oral arithmetic (Wechsler Adult Intelligence Scale-Third Edition [WAIS-III] Arithmetic subtest) and written arithmetic (Wide Range Achievement Test-3 [WRAT-3] Arithmetic subtest) were administered, and overall group differences were examined. Errors on selected WRAT-3 problems were qualitatively analyzed across groups using a set of error codes. Patients with mild and moderate AD performed significantly below controls on both oral and written arithmetic tasks (P<.001). Patients with moderate AD performed worse than those with mild AD on written arithmetic (P<.002) but not on oral arithmetic tasks. On selected WRAT-3 problems, single- and multiple-digit addition and subtraction operations and single-digit division operations were preserved in patients with mild AD. In contrast, only single-digit addition was preserved in patients with moderate AD. Errors of operation substitution and number position were the most common error types observed in AD patients. Patients with moderate AD displayed multiple error types and high incidence rates compared with controls, while patients with mild AD exhibited error types and incidence rates intermediate to controls and patients with moderate AD. A decline in calculation abilities is one of the hallmark cognitive features of AD. Patients with mild AD maintain relative preservation of simple written calculation skills but demonstrate marked impairment as task complexity increases. Patients with moderate AD demonstrate global impairments extending to the simplest arithmetic skills. These findings suggest that loss of calculation abilities in AD is both hierarchical (by arithmetic operation) and a function of disease severity.
- Research Article
7
- 10.4103/1673-5374.346485
- Jan 1, 2023
- Neural Regeneration Research
CD34+ progenitor cells as diagnostic and therapeutic targets in Alzheimer's disease.
- Research Article
82
- 10.1016/j.ajpath.2013.10.002
- Dec 12, 2013
- The American Journal of Pathology
High Activities of BACE1 in Brains with Mild Cognitive Impairment
- Research Article
- 10.1089/genbio.2023.29090.aas
- Apr 1, 2023
- GEN Biotechnology
Moving Beyond Amyloid in Alzheimer's Therapeutics
- Research Article
8
- 10.1016/j.heliyon.2023.e19485
- Aug 25, 2023
- Heliyon
A leaky gut contributes to postural dysfunction in patients with Alzheimer's disease
- Research Article
8
- 10.3760/cma.j.cn112137-20220406-00715
- Sep 20, 2022
- Zhonghua yi xue za zhi
Objective: To analyze the correlation of muscle strength with cognitive function and medial temporal lobe atrophy (MTA) in patients with mild to moderate Alzheimer's disease (AD). Methods: General information, sarcopenia-related indicators, neuropsychological tests and MTA score were collected in 80 confirmed AD patients (41 mild and 39 moderate patients) and 43 normal controls (NC) from the Memory Disorders Clinic of Department Of Neurology in the Second Affiliated Hospital of Soochow University between January and December 2021. Appendicular skeletal muscle mass index (ASMI), grip strength and 5-times sit-to-stand time and 6-m gait speed were used for assessing muscle mass, muscle strength and physical function, respectively. Cognitive function was assessed by Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment scale (MoCA), Memory and Executive Screening Scale (MES), Digit Symbol Substitution Test (DSST), Digital Span Test (DST) and Verbal Fluency Task (VFT), respectively. DST included Forward Digit Span Test (FDST) and Backward Digit Span Test (BDST). All the subjects underwent 3.0T coronal three-dimensional gradient echo sequence MRI. MTA scale was performed to evaluate the degree of medial temporal lobe atrophy. The differences in the sarcopenia-related indicators, cognitive score and MTA score were analyzed among the three groups, and the partial correlation analysis was performed between the inter-groups. Results: Eighty AD patients (24 males and 56 females) were included, aged (72±7) years old, with 41 mild and 39 moderate patients. Meanwhile, 43 NC included 19 males and 24 females, with a mean age of (70±6) years old. The disease duration in moderate AD patients was longer than that of mild AD patients [34.0 (25.0, 43.5) months vs 24.0 (11.0, 34.0) months, P<0.001]. The differences of sarcopenia-related indicators and MTA score among the three groups were statistically significant (all P<0.001), including 5-times sit-to-stand time [(13.6±1.8) s vs (11.5±1.7) s vs (10.3±1.9) s, P<0.001] and MTA score [2.0 (2.0, 3.0) vs 1.0 (1.0, 2.0) vs 0 (0, 0), P<0.001]. In neuropsychological tests, compared to the NC group, MMSE, MoCA, MES and VFT scores in mild and moderate AD groups were lower (all P<0.001); meanwhile, compared to the mild AD group, the moderate group had lower MMSE, MoCA, MES, DSST and VFT scores (all P<0.001). In sarcopenia-related indicators, muscle strength in particular was correlated with widespread cognitive functioning domains and MTA score in AD patients. Grip strength was positively correlated with MMSE, MoCA , MES, FDST (r=0.387, 0.418, 0.522 and 0.484, respectively, all P<0.001), DSST (r=0.327, P=0.006) and VFT score (r=0.354, P=0.003), and negatively correlated with MTA score (r=-0.631, P<0.001). 5-times sit-to-stand time was negatively correlated with MMSE, MoCA, MES, DSST, FDST, VFT score (r=-0.583, -0.587, -0.814, -0.591, -0.552 and -0.485, respectively, all P<0.001), and BDST (r=-0.355, P=0.003) strongly positively correlated with MTA score (r=0.836, P<0.001). ASMI was positively correlated with MMSE, MoCA, MES, DSST, FDST score (r=0.257, 0.238, 0.428, 0.282 and 0.364, respectively, all P<0.05), and negatively correlated with MTA score (r=-0.377, P=0.001). 6-m gait speed was positively correlated with MMSE, MoCA, MES, DSST, FDST score (r=0.419, 0.486, 0.699, 0.559 and 0.500, respectively, all P<0.001), BDST and VFT score (r=0.384、0.377, respectively, both P=0.001), and strongly negatively correlated with MTA score (r=-0.803, P<0.001). Conclusions: Patients with mild to moderate AD have widespread cognitive impairment. Muscle mass, muscle strength and physical function are all significantly impaired. Compared to muscle mass and physical function, decreased muscle strength is significantly associated with widespread cognitive decline and increased degree of medial temporal lobe atrophy.
- Research Article
31
- 10.1016/j.archger.2009.11.004
- Nov 30, 2009
- Archives of Gerontology and Geriatrics
Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: Implications for early diagnosis and treatment
- Research Article
- 10.1044/2025_jslhr-24-00602
- Sep 10, 2025
- Journal of speech, language, and hearing research : JSLHR
This study aimed to investigate the changes and deterioration in lexical processing caused by Alzheimer's disease (AD). It analyzed the differences in lexical processing between individuals with healthy controls, mild AD, and moderate AD as well as how these groups processed varying lexical aspects. A total of 180 older adults participated in the experiment, including 60 healthy controls, 60 with mild AD, and 60 with moderate AD. Each group was further divided into two subgroups, with each subgroup assigned to one of two different experiments. The experiments assessed the speed and accuracy of lexical processing in both orthography and meaning using compound words. Individuals with mild and moderate AD showed significant differences in the speed and accuracy of lexical processing, both in orthography and meaning, compared to healthy controls. When the prime character shared character-level units with the target word, it enhanced the accuracy of lexical processing in AD patients. Mild AD patients demonstrated a significant advantage in both the speed and accuracy of processing high-frequency words in terms of orthography and meaning, while moderate AD patients only showed a significant advantage in orthographic processing accuracy. The AD group showed no significant differences in the speed and accuracy of processing high- and low-transparency words in terms of orthographic and meaning processing. Lexical processing significantly deteriorated in individuals with AD, with a greater decline observed in those with moderate AD. Differences in lexical processing between mild and moderate AD patients highlighted the varying impact of the disease's severity.
- Research Article
- 10.6200/tcmj.2014.11.3.02
- Sep 30, 2014
Objectives: Self awareness is progressively vanishing in Alzheimer's disease (AD) patients, while insight of amnesia seemingly stays longer than self awareness. It is clinically informative to prove that the residual learning ability of the patients exists, though defective, to help construct a better individualized rehabilitative strategy. Methods: Eighty-one patients (M:F=28:53), aged 59~102, with AD dementia were divided into four groups by mini-mental status examination (MMSE) scores (early: >/=21, n=16; mild: 16-20, n= 19; moderate: 11-15, n=30; severe: </=10, n=16). Each group was tested for 1) self awareness by asking each individual name, age, birthday and children number, 2) visual confrontation naming of 3 presented objects, namely pencil, comb, and key, and 3) insight of amnesia by asking whether or not they have memory problems. Only completing right answers to all items in each test was counted as correct response (CR). Numbers of CR in each test were collected for analysis. Results: A concordant trend was noted between the severity of AD and test results. In mild and moderate AD patients whose self awareness were vanishing (CR=42%→0%), the insight of amnesia remained to a significant degree (CR=84%→60%). In early AD, four patients denied memory problems. The test result of confrontation naming was closer to that of insight of amnesia in mild and moderate AD patients, as compared to that of self awareness. Conclusions: While self awareness is vanishing in mild and moderate AD patients, their insight of amnesia remained to a significant degree, suggesting a learning effect. The learned insight of amnesia, through daily interaction, stays longer and stronger than self awareness in mild to severe AD patients. The four patients in their early AD denying memory problems did not learn from environmental feedbacks. The closer test results of insight of amnesia with confrontation naming in mild and moderate AD patients suggest a cortical language learning process. The potential of learning in AD patients sheds guiding light on rehabilitative strategy in mild and moderate AD.
- Research Article
16
- 10.1007/s00330-017-4865-1
- Jun 2, 2017
- European Radiology
To validate the value of whole-brain computed tomography perfusion (CTP) and CT angiography (CTA) in the diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD). Whole-brain CTP and four-dimensional CT angiography (4D-CTA) images were acquired in 30 MCI, 35 mild AD patients, 35 moderate AD patients, 30 severe AD patients and 50 normal controls (NC). Cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), time to peak (TTP), and correlation between CTP and 4D-CTA were analysed. Elevated CBF in the left frontal and temporal cortex was found in MCI compared with the NC group. However, TTP was increased in the left hippocampus in mild AD patients compared with NC. In moderate and severe AD patients, hypoperfusion was found in multiple brain areas compared with NC. Finally, we found that the extent of arterial stenosis was negatively correlated with CBF in partial cerebral cortex and hippocampus, and positively correlated with TTP in these areas of AD and MCI patients. Our findings suggest that whole-brain CTP and 4D-CTA could serve as a diagnostic modality in distinguishing MCI and AD, and predicting conversion from MCI based on TTP of left hippocampus. • Whole-brain perfusion using the full 160-mm width of 320 detector rows • Provide clinical experience of 320-row CT in cerebrovascular disorders of Alzheimer's disease • Initial combined 4D CTA-CTP data analysed perfusion and correlated with CT angiography • Whole-brain CTP and 4D-CTA have high value for monitoring MCI to AD progression • TTP in the left hippocampus may predict the transition from MCI to AD.
- Research Article
59
- 10.1016/j.jns.2006.09.014
- Nov 9, 2006
- Journal of the Neurological Sciences
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment
- Research Article
42
- 10.1016/j.jbc.2021.100489
- Jan 1, 2021
- The Journal of Biological Chemistry
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
- Research Article
36
- 10.1111/ene.12546
- Aug 21, 2014
- European Journal of Neurology
Whilst there is evidence implicating small vessel cerebrovascular disease in the pathogenesis of Alzheimer's disease (AD), its specific contribution to the pathophysiology of AD remains unclear. The burden of small vessel cerebrovascular disease visualized as white matter hyperintensity (WMH) and its association with medial temporal atrophy (MTA) at different stages of AD was studied. One hundred and sixty-five cognitively normal (CN) community controls, 103 mild cognitive impairment (MCI) patients, 141 mild AD patients and 68 moderate-severe AD patients were studied. Clinical, cognitive and risk factor data were collected, and WMH and MTA were quantified by trained raters. The Jonckheere-Terpstra test for ordered alternatives was used to study the association between WMH and MTA in different stages of AD. The burden of total WMH increased significantly with increasing severity of AD, even after correcting for confounders. The proportion of CN, MCI, mild AD and moderate-severe AD subjects with severe burden of WMH was 6.7%, 9.7%, 28.4%, and 39.7%, respectively. A strong positive association between WMH severity and MTA was evident amongst MCI (P = 0.011) and mild AD (P = 0.003) subjects, but not in CN (P = 0.953) and moderate-severe AD subjects (P = 0.301). The burden of WMH increased significantly from the stage of CN to MCI to AD. The association between WMH and MTA was greatest at the stage of MCI and mild AD. This has implications on the strategy to slow the progression of AD, where measures to reduce WMH, including control of vascular risk factors, need to be optimized at the stage of MCI and mild AD.
- Research Article
2
- 10.1186/s13578-024-01241-5
- May 23, 2024
- Cell & Bioscience
- Research Article
- 10.1186/s13578-024-01247-z
- May 22, 2024
- Cell & Bioscience
- Research Article
10
- 10.1186/s13578-024-01245-1
- May 17, 2024
- Cell & Bioscience
- Research Article
4
- 10.1186/s13578-024-01244-2
- May 15, 2024
- Cell & Bioscience
- Research Article
7
- 10.1186/s13578-024-01240-6
- May 12, 2024
- Cell & Bioscience
- Research Article
1
- 10.1186/s13578-024-01246-0
- May 11, 2024
- Cell & Bioscience
- Research Article
3
- 10.1186/s13578-024-01236-2
- May 9, 2024
- Cell & Bioscience
- Research Article
8
- 10.1186/s13578-024-01242-4
- May 8, 2024
- Cell & Bioscience
- Research Article
3
- 10.1186/s13578-024-01238-0
- May 4, 2024
- Cell & Bioscience
- Research Article
6
- 10.1186/s13578-024-01239-z
- May 2, 2024
- Cell & Bioscience
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.